Antoine Hage, MD
Advanced Heart Failure and Transplant Cardiology · Beverly Hills, CANPI 1467540203
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 26.2% of the total. Reporting peaked in 2022 at $210 and has fallen 74.4% since, to $54 in 2024. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 14 payments — averaging $57.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$210
- Bayer$200
- United Therapeutics Corporation$191
- Medtronic$106
- Merck$55
- Sandoz$21
- plus $18 from 1 others
Across 106 payments — averaging $8548.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$583K
- United Therapeutics Corporation$171K
- Insmed, Inc.$59K
- Astrazeneca UK Limited$47K
- Bayer$26K
- Janssen Research & Development, LLC$14K
- plus $5K from 1 others
What the payments were for
- Consulting fees$20025%
- Speaking & faculty fees$10012%
- Food & beverage$31139%
- Education$19024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 4 | $210 |
| Bayer | 1 | $200 |
| United Therapeutics Corporation | 3 | $191 |
| Medtronic | 1 | $106 |
| Merck | 3 | $55 |
| Sandoz | 1 | $21 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
- HeartWare HVAD$106
How this compares
$801 in reported general payments places this provider in the 10th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 65 | $1,175,975 |
| Tyvaso DpiTreprostinil | 35 | $789,285 |
| OpsumitMacitentan | 40 | $495,968 |
| VyndamaxTafamidis | 15 | $388,689 |
| AdempasRiociguat | 30 | $384,911 |
| Ambrisentan | 81 | $329,972 |
| EliquisApixaban | 109 | $126,664 |
| LetairisAmbrisentan | 13 | $85,414 |
| EntrestoSacubitril/Valsartan | 52 | $65,100 |
| XareltoRivaroxaban | 45 | $59,278 |
| JardianceEmpagliflozin | 41 | $52,764 |
| FarxigaDapagliflozin Propanediol | 44 | $49,649 |
| Repatha SureclickEvolocumab | 18 | $22,673 |
| Praluent PenAlirocumab | 23 | $16,395 |
| OzempicSemaglutide | 14 | $13,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $210 | $1,671,943105 claims |
| BayerAdempas | $200 | $384,91130 claims |
| GileadLetairis | $18 | $85,41413 claims |
| SandozEnoxaparin Sodium | $21 | $1,11312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Beverly Hills
- Jignesh PatelBeverly Hills$176K
- Lily SternBeverly Hills$32K
- Jaime MoriguchiBeverly Hills$20K
- Michele HamiltonBeverly Hills$17K
- Kambiz GhafourianBeverly Hills$9K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.